Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/ml vs. insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring (CGM): a randomized crossover study
ConclusionsCompared to L+GB, G+G300 decreases post‐breakfast glucose level reducing rate of rise, nocturnal and 24‐h glucose variability and level without causing hypoglycemia, and daily variance.This article is protected by copyright. All rights reserved. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - March 1, 2017 Category: Endocrinology Authors: Soichi Takeishi, Hiroki Tsuboi, Shodo Takegoshi Tags: Original Article Source Type: research
Economic outcomes with the conversion of insulin delivery methods in hospitals.
CONCLUSION: Switching RAI from IPS of 3-mL pens of insulin aspart to one-time unit dose insulin lispro dispensed from FS 3-mL vials as needed significantly reduced insulin wastage and associated acquisition costs at the 3 combined hospitals. Conversion of basal insulin from IPS of 3-mL pens of insulin detemir to CUD of 10-mL vials of insulin detemir was associated with a significant reduction in insulin wastage and associated acquisition costs at 3 hospitals combined.
PMID: 28133990 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 1, 2017 Category: Health Management Tags: J Med Econ Source Type: research
Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus.
CONCLUSION: This analysis found treatment with exenatide twice daily improved glycemic control without weight gain in Korean patients with T2DM unable to achieve glycemic control on metformin plus basal insulin.
PMID: 28029018 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 29, 2016 Category: Endocrinology Tags: Diabetes Metab J Source Type: research
Similar pharmacokinetics and pharmacodynamics of rapid ‐acting insulin lispro products SAR342434 and US‐ and EU‐approved Humalog® in subjects with type 1 diabetes
ConclusionsThe results of this study demonstrate similarity in insulin lispro exposure profiles and PD activity of SAR342434 solution to both US‐ and EU‐approved Humalog®, and between both US‐ and EU‐approved Humalog®, supporting SAR342434 solution for injection as a follow‐on product. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - December 16, 2016 Category: Endocrinology Authors: C. Kapitza, I. Nowotny, A. Lehmann, K. Bergmann, B. Rotthaeuser, L. Nosek, R. Becker Tags: ORIGINAL ARTICLE Source Type: research
Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes.
CONCLUSION: Smaller decreases in FHG were associated with not reaching the target HbA1c, suggesting a need to increase basal or premixed insulin doses to achieve targeted fasting plasma glucose and improve patient response before introducing more intensive prandial insulin regimens.
PMID: 27988180 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - December 13, 2016 Category: Endocrinology Authors: Scheen AJ, Schmitt H, Jiang HH, Ivanyi T Tags: Diabetes Metab Source Type: research
Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial
This study is registered with ClinicalTrials.gov, number NCT01845831. Findings Between Aug 23, 2013, and July 27, 2015, we recruited 279 patients, and randomly assigned 277 to treatment; 138 to sitagliptin–basal and 139 to basal–bolus. The length of stay in hospital was similar for both groups (median 4 days [IQR 3–8] vs 4 [3–8] days, p=0·54). The mean daily blood glucose concentration in the sitagliptin–basal group (9·5 mmol/L [SD 2·7]) was not inferior to that in the basal–bolus group 9·4 mmol/L [2·7]) with a mean blood glucose difference of 0·1 mmol/L (95% CI −0·6 to 0·7). No deaths occurred in th...
Source: The Lancet Diabetes and Endocrinology - December 7, 2016 Category: Endocrinology Source Type: research
Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals
ConclusionThis work demonstrates that increasing the hydrodynamic size of insulin lispro through PEGylation can impact both absorption and clearance to prolong drug action. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - November 3, 2016 Category: Drugs & Pharmacology Source Type: research
Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial
ConclusionsGlycemic control improved in both LM25 and LM50 groups, but LM50 was significantly more efficacious under certain dietary conditions, particularly with increased carbohydrate intake.
Diet plays an important role when tailoring anti‐diabetic treatment, however the evidence is little from randomized clinical trial. In this study, we found both LM25 and LM50 improved Glycemic control in East Asian with T2DM, but LM50 was significantly more efficacious under certain dietary conditions, particularly with increased carbohydrate intake. (Source: Journal of Diabetes Investigation)
Source: Journal of Diabetes Investigation - October 4, 2016 Category: Endocrinology Authors: Wei Chen, Lei Qian, Hirotaka Watada, Peng Fei Li, Noriyuki Iwamoto, Makoto Imori, Wen Ying Yang Tags: Clinical Trial Source Type: research
Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American ... (Source: Diabetology and Metabolic Syndrome)
Source: Diabetology and Metabolic Syndrome - September 17, 2016 Category: Endocrinology Authors: Arturo Rojas, Georgina Sposetti, Jorge L. Gross, Douglas Eugenio Barbieri, Ran Duan, Bruno Linetzky, Janaina Martins De Lana, Oded Stempa and Angel Rodriguez Source Type: research
Challenges of LADA Diagnosis and Treatment: Lessons From 2 Case Reports
Latent autoimmune diabetes in adults (LADA) is a subtype of autoimmune diabetes, which shares characteristics of both Type 1 and 2 diabetes (T1D and T2D), and for this reason, it is often confused with other types of diabetes, misdiagnosed, and inappropriately treated. Two cases were presented (41-year-old and 50-year-old females), one occasionally diagnosed during routine health checkup, the other one identified as having T2D, and as far as misclassified and not optimally treated. Now, after approximately 9 months of LADA diagnosis, the first patient has an optimal metabolic control while maintaining the values of glycate...
Source: American Journal of Therapeutics - September 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control
CONCLUSIONS
Insulin absorption and action are blunted and considerably more variable with LHT injection, leading to profound deterioration in postprandial glucose control. (Source: Diabetes Care)
Source: Diabetes Care - August 22, 2016 Category: Endocrinology Authors: Famulla, S.; Hövelmann, U.; Fischer, A.; Coester, H.-V.; Hermanski, L.; Kaltheuner, M.; Kaltheuner, L.; Heinemann, L.; Heise, T.; Hirsch, L. Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
Randomized, double ‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
ConclusionsIn patients with type 1 diabetes, treatment with BIL compared with GL for 52 weeks resulted in a lower HbA1c, more patients with HbA1c levels <7%, and reduced nocturnal hypoglycaemia, but more total hypoglycaemia and injection site reactions and higher triglyceride and ALT levels. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - August 2, 2016 Category: Endocrinology Authors: R. M. Bergenstal, H. Lunt, E. Franek, F. Travert, J. Mou, Y. Qu, C. J. Antalis, M. L. Hartman, M. Rosilio, S. J. Jacober, E. J. Bastyr, Tags: ORIGINAL ARTICLE Source Type: research
Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon ‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD‐4 substudy
ConclusionsIn combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - July 21, 2016 Category: Endocrinology Authors: Johan Jendle, Marcia A. Testa, Sherry Martin, Honghua Jiang, Zvonko Milicevic Tags: ORIGINAL ARTICLE Source Type: research
20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence
ConclusionsFor almost 20 years, rapid‐acting insulins, in particular insulin lispro as the first‐in‐class, have contributed to broadening the treatment options for the unique needs of pediatric patients with type‐1‐diabetes across all age‐groups, and have enabled more physiological insulin administration. Now widely used, they have allowed pediatric patients to safely reach better glycemic control, with more flexibility in their daily lives. (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - July 8, 2016 Category: Endocrinology Authors: Kevin Kaiserman, Heike Jung, Imane Benabbad, Beate Karges, Michel Polak, Myriam Rosilio Tags: Review Article Source Type: research
A Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine, in Combination with Prandial insulin Lispro, in Patients with Type 1 Diabetes: IMAGINE 1
ConclusionsIn patients with type 1 diabetes, treatment with BIL compared to GL for 26 weeks was associated with lower HbA1c, less nocturnal hypoglycemia, lower glucose variability, and weight loss. Increases in total and severe hypoglycemia, triglycerides, aminotransferases, and injection site reactions were also noted.Funded by Eli Lilly and Company. Registered at clinicaltrials.gov (NCT01481779). (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - July 7, 2016 Category: Endocrinology Authors: Satish Garg, Manfred Dreyer, Hideaki Jinnouchi, Jiani Mou, Yongming Qu, Mark L. Hartman, Myriam Rosilio, Scott J. Jacober, Edward J. Bastyr III, Tags: REVIEW ARTICLE Source Type: research
